U.S. Markets open in 4 hrs 4 mins
  • S&P Futures

    3,787.50
    +25.25 (+0.67%)
     
  • Dow Futures

    30,879.00
    +159.00 (+0.52%)
     
  • Nasdaq Futures

    12,925.75
    +123.50 (+0.96%)
     
  • Russell 2000 Futures

    2,146.50
    +25.70 (+1.21%)
     
  • Crude Oil

    52.49
    +0.13 (+0.25%)
     
  • Gold

    1,842.50
    +12.60 (+0.69%)
     
  • Silver

    25.44
    +0.58 (+2.33%)
     
  • EUR/USD

    1.2130
    +0.0047 (+0.3882%)
     
  • 10-Yr Bond

    1.0970
    0.0000 (0.00%)
     
  • Vix

    22.85
    -0.40 (-1.72%)
     
  • GBP/USD

    1.3619
    +0.0032 (+0.2370%)
     
  • USD/JPY

    103.9920
    +0.3050 (+0.2942%)
     
  • BTC-USD

    37,207.84
    +766.11 (+2.10%)
     
  • CMC Crypto 200

    735.31
    +0.17 (+0.02%)
     
  • FTSE 100

    6,732.94
    +12.29 (+0.18%)
     
  • Nikkei 225

    28,633.46
    +391.25 (+1.39%)
     

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Prevail Therapeutics, Inc. - PRVL

·2 min read

NEW YORK, Dec. 18, 2020 /PRNewswire/ --

Monteverde & Associates PC Logo
Monteverde & Associates PC Logo

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Prevail Therapeutics, Inc. ("Prevail" or the "Company") (PRVL) relating to its proposed acquisition by Eli Lilly and Company. Under the terms of the agreement, Prevail shareholders will receive $22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to $4.00 per share.

The investigation focuses on whether Prevail Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether and by how much this proposed transaction undervalues the Company.

Click here for more information: https://www.monteverdelaw.com/case/prevail-therapeutics-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant Prevail litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in Prevail Therapeutics, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-prevail-therapeutics-inc--prvl-301196292.html

SOURCE Monteverde & Associates PC